by Bioblast Editor | Mar 16, 2019 | Biosimilars updates
PBAC Committee recommends all 4 brands of Celltrion biosimilar products (Tuxella®, Rituzena®, Ritemvia®, Truxima) for PBS listing in AU for all TGA registered indications for which the reference brand Mabthera is currently listed on the PBS, despite approved skinny...
by Bioblast Editor | Mar 1, 2019 | Biosimilars updates
Celltrion gains Australian approval for biosimilar rituximab under two product names, Rituzena® and Tuxella®.
